Cash, cash equivalents and marketable securities were $413.3M as of September 30. The company’s cash, cash equivalents and marketable securities as of September 30 in combination with the net proceeds from the public offering of approximately $282M, are expected to extend the company’s operating runway into 2027. “This has been another incredible year of execution for Nuvalent. With our recent presentation at ANE, we have now delivered preliminary proof-of-concept data for both of our novel parallel lead programs in ROS1 and ALK-positive cancers, and our third development candidate, NVL-330, is advancing toward clinical development,” said James Porter, CEO at Nuvalent. “This level of achievement in just over five years since first program inception is only made possible by the tireless dedication of our team to our goal of delivering potential new therapies to patients as quickly as possible.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NUVL:
- Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
- Nuvalent director sells $4.65M in common stock
- Nuvalent price target raised to $79 from $73 at BMO Capital
- Nuvalent 5.36M share Spot Secondary priced at $56.00
- Nuvalent price target raised to $69 from $42 at Leerink
